Statin exposure and risk of revision hip and knee arthroplasty

  • Cook MJ & al.
  • J Rheumatol
  • 15 Mar 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Statin therapy is associated with a reduced risk of revision hip and knee surgery.
  • Timing of first exposure to statin therapy appear to influence the risk of revision surgery with first exposure within 5 years of surgery being associated with a reduction in risk.

Why this matters

  • Findings suggest that statins may potentially provide an approach to reducing the risk of revision surgery in patients undergoing primary THA/TKA.

Study design

  • Study used data from the Clinical Practice Research Datalink (CPRD) and identified 151,305 participants who underwent a primary THA (n=78,594) or TKA (n=72,711) from 1988 -2016.
  • Primary outcome: all-cause revision arthroplasty.
  • Funding: John Charnley Trust and others.

Key results

  • Of 151,305 participants, 65,032 (43%) were exposed to statins during follow-up and 3500 (2.3%) had revision arthroplasty.
  • In a propensity score adjusted model, statins exposure was associated with a lower risk for revision arthroplasty vs non-exposure (aHR, 0.82; 95% CI, 0.75-0.90).
  • Participants first exposed to statins in 0-1 year (aHR, 0.82; 95% CI, 0.74-0.91), 1-5 years (aHR, 0.76; 95% CI, 0.65-0.90) and >5 years (aHR, 0.95; 95% CI, 0.76-1.19) following THA/TKA had a reduced risk for revision arthroplasty vs those not exposed.
  • Compared to participants exposed to statins for 5 years had lower risk for revision arthroplasty (aHR, 0.74; 95% CI, 0.62-0.88).

Limitations

  • Observational design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit